How can we reduce the mortality of invasive pneumococcal disease?

Welte T.

Source: Eur Respir Rev 2012; 21: 6-7

Journal Issue: March 2012 - 21 (123)

Disease area: Respiratory critical care

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Welte T.. How can we reduce the mortality of invasive pneumococcal disease?. Eur Respir Rev 2012; 21: 6-7

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

The problem of early mortality in pneumococcal pneumonia: a study of risk factors Source: Eur Respir J 2015; 46: 561-564 Year: 2015
CURB-65 clinical prediction rule in invasive pneumococcal disease (IPD) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012
Bacteremic pneumococcal pneumonia is associated with an increased rate of cardiovascular events Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis Year: 2019
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005
Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia Source: Eur Respir J 2014; 43: 36-42 Year: 2004
Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009
Chronic pulmonary diseases and the epidemiology of invasive pneumococcal infection Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012
Societal perspective and challenges of influenza and pneumococcal vaccination in patients at risk of respiratory complications Source: Annual Congress 2008 - Why vaccinate patients with chronic respiratory conditions? Today and tomorrow's perspectives Year: 2008
Immunosuppression is associated with lower morbidity and mortality in the 2017/2018 influenza epidemic Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019
Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types Source: Eur Respir J 2014; 44: 1646-1657 Year: 2014
Vaccination rates against pneumococcal and influenza infection in hospitalized cardiologic and pneumologic patients need to be improved. Source: International Congress 2018 – Respiratory epidemiology: from infectious diseases to lung cancer Year: 2018
Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes Source: Eur Respir J 2014; 43: 545-553 Year: 2013
Influenza and pneumoccocal vaccination protect against all cause mortality in COPD Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Results of vaccination against pneumococcal infection in patients with chronic lung diseases Source: International Congress 2019 – Airway infection in COPD Year: 2019
Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007
Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007